Shots:
- MD Anderson to receive payments based on the development and commercialization of Schrödinger’s WEE1 inhibitor compounds. Schrödinger to provide research funding & will unite with researchers in MD Anderson’s TRACTION platform to accelerate the development of new therapies
- Schrödinger will be responsible to develop, manufacture & commercialize the products & gets the rights to all novel intellectual property
- The focus of the collaboration is to accelerate & optimize the development of the WEE1 program through molecular biomarker-driven tumor type prioritization, patient stratification & validate biomarkers to predict response or resistance to a WEE1 inhibitor
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Schrödinger Signs a Two-Year Research Collaboration with MD Anderson to Advance its WEE1 Program first appeared on PharmaShots.
